David Lacey
Direktor/Vorstandsmitglied bei NURIX THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 30.04.2024
Profil
Dr. David L.
Lacey, MD, is a Venture Partner at Ysios Capital Partners SGEIC SA, an Independent Director at Arcus Biosciences, Inc., an Independent Director at Atreca, Inc. and an Independent Non-Executive Director at Inbiomotion SL.
He is on the Board of Directors at Arcus Biosciences, Inc., Atreca, Inc., Nurix Therapeutics, Inc. and Inbiomotion SL.
Dr. Lacey was previously employed as an Independent Director by Unity Biotechnology, Inc., an Independent Non-Executive Director by argenx SE, a Senior Vice President-Discovery Research by Amgen, Inc., an Assistant Professor by Jewish Hospital, and an Associate by The University of Colorado.
He also served on the board at Rainier Therapeutics, Inc. He received his undergraduate degree from The University of Colorado and a doctorate degree from The University of Colorado School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0,05% | 01.03.2024 | 42 452 ( 0,05% ) | 625 318 $ | 30.04.2024 |
NURIX THERAPEUTICS, INC.
0,06% | 20.05.2024 | 33 333 ( 0,06% ) | 411 996 $ | 30.04.2024 |
Aktive Positionen von David Lacey
| Unternehmen | Position | Beginn |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 20.05.2024 |
| ATRECA, INC. | Direktor/Vorstandsmitglied | 31.05.2016 |
| ARCUS BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 21.05.2020 |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Direktor/Vorstandsmitglied | 01.12.2012 |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Private Equity Investor | 01.06.2020 |
Ehemalige bekannte Positionen von David Lacey
| Unternehmen | Position | Ende |
|---|---|---|
| ARGENX SE | Direktor/Vorstandsmitglied | 11.05.2021 |
| UNITY BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 14.12.2020 |
| AMGEN INC. | Corporate Officer/Principal | 01.01.2011 |
| The University of Colorado | Corporate Officer/Principal | - |
| ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von David Lacey
| The University of Colorado | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| ARGENX SE | Health Technology |
| AMGEN INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Health Technology |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Jewish Hospital
 Jewish Hospital Hospital/Nursing ManagementHealth Services Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million. | Health Services |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Finance |
